Staphylococcus aureus AtlE Crystal Structure for Antibiotic Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective targets for treating antibiotic-resistant Staphylococcus aureus infections, as existing antibiotics have developed resistance, and there is a need for alternative approaches to address the bacterial cell wall degradation enzymes involved in biofilm formation and pathogenesis.
Innovation Solution
The development of a crystal structure of autolysin E (AtlE) from Staphylococcus aureus, along with a method for producing its crystal and a crystallization kit, enables the screening of inhibitors for N-acetylglucosaminidase activity and identification of binding compounds for GH73 family glucosaminidases, utilizing atomic spatial relationship data and in silico screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat S. aureus infections, then bacterial infections can be treated, but antibiotic resistance develops making treatments ineffective
Solution Approach 1:
The patent extracts and targets a specific enzyme (AtlE glucosaminidase) from the bacterial cell wall degradation pathway as a novel therapeutic target. By focusing on this specific enzyme rather than using broad-spectrum antibiotics, the treatment can inhibit bacterial pathogenesis without selecting for general antibiotic resistance, thus resolving the contradiction between treatment effectiveness and resistance development
Solution Approach 2:
The invention applies local quality by designing inhibitors that specifically target the unique active site structure of AtlE glucosaminidase. The crystal structure reveals distinct structural features of the active site that allow for highly specific inhibitor design, enabling targeted inhibition of this enzyme's function in cell wall degradation and biofilm formation without affecting other bacterial processes or selecting for broad resistance
2Measurement precision
If crystal structure determination methods are used to identify enzyme inhibitors, then specific binding compounds can be identified, but the process requires complex structural biology techniques and time-consuming screening
Solution Approach 1:
The patent performs preliminary action by determining the crystal structure of AtlE glucosaminidase and characterizing its active site features before conducting inhibitor screening. This pre-characterization of the target structure allows for rational drug design and in silico screening approaches, reducing the need for extensive experimental screening while maintaining high precision in identifying binding compounds
Solution Approach 2:
The invention uses computational copying by creating in silico models of the AtlE active site based on the crystal structure. These computational models can be used for virtual screening of compound libraries, allowing researchers to identify potential inhibitors through computer-based fitting operations before validating them experimentally, thus reducing the complexity and time of the overall screening process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of novel inhibitors targeting specific enzymes, potentially leading to the development of effective antibiotics against antibiotic-resistant Staphylococcus aureus by exploiting the unique active site of AtlE and understanding the distinct pathways of glucosaminidases and muramidases.
Implementation Method 1
The present invention concerns the determination and evaluation of the crystal structure of Autolysin E (AtlE) of Staphylococcus aureus (S. aureus)... for obtaining atomic spatial relationship data
Implementation Method 2
a method for producing a crystal of AtlE and the respective crystallization kit
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention concerns the determination and evaluation of the crystal structure of autolysin E (AtlE) of Staphylococcus aureus (S. aureus), or a crystallizable fragment of AtlE, a method for producing a crystal of AtlE and the respective crystallization kit, and its use in a method for screening an inhibitor of the N-acetylglucosaminidase activity of AtlE, for obtaining atomic spatial relationship data, and for identifying a binding compound of AtlE, e.g. by in silico screening.